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Background: Alzheimer’s disease (AD) is the most common form of dementia, the number of affected individuals
is rising, with significant impacts for healthcare systems. Current symptomatic treatments delay, but do not halt,
disease progression. Genetic evidence points to aggregation and deposition of amyloid-β (Aβ) in the brain being
causal for the neurodegeneration and dementia typical of AD. Approaches to target Aβ via inhibition of γ-secretase
or passive antibody therapy have not yet resulted in substantial clinical benefits. Inhibition of BACE1 (β-secretase)
has proven a challenging concept, but recent BACE1inhibitors can enter the brain sufficiently well to lower Aβ.
However, failures with the first clinical BACE1 inhibitors have highlighted the need to generate compounds with
appropriate efficacy and safety profiles, since long treatment periods are expected to be necessary in humans.
Results: Treatment with NB-360, a potent and brain penetrable BACE-1 inhibitor can completely block the
progression of Aβ deposition in the brains of APP transgenic mice, a model for amyloid pathology. We furthermore
show that almost complete reduction of Aβ was achieved also in rats and in dogs, suggesting that these findings
are translational across species and can be extrapolated to humans. Amyloid pathology may be an initial step in a
complex pathological cascade; therefore we investigated the effect of BACE-1 inhibition on neuroinflammation, a
prominent downstream feature of the disease. NB-360 stopped accumulation of activated inflammatory cells in the
brains of APP transgenic mice. Upon chronic treatment of APP transgenic mice, patches of grey hairs appeared.
Conclusions: In a rapidly developing field, the data on NB-360 broaden the chemical space and expand
knowledge on the properties that are needed to make a BACE-1 inhibitor potent and safe enough for long-term
use in patients. Due to its excellent brain penetration, reasonable oral doses of NB-360 were sufficient to
completely block amyloid-β deposition in an APP transgenic mouse model. Data across species suggest similar
treatment effects can possibly be achieved in humans. The reduced neuroinflammation upon amyloid reduction by
NB-360 treatment supports the notion that targeting amyloid-β pathology can have beneficial downstream effects
on the progression of Alzheimer’s disease.
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Alzheimer’s disease (AD) is the most common form of
senile dementia, with increasing incidence as a function of
age. It poses a significant challenge to the healthcare
systems in both industrial and developing countries. Major
efforts to find disease-modifying therapies have focused on
the key pathological alterations in AD brains, aggregation
of β-amyloid (Aβ) and tau protein aggregation. Aβ peptides
are being constantly generated from the precursor APP in
the normal brain but their concentrations remain low due
to the presence of effective clearance mechanisms. During
disease development, insoluble forms accumulate in cor-
tical and subcortical brain areas. Substantial evidence sup-
ports the concept that neurotoxicity of aggregated Aβ
isoforms and/or Aβ-induced neuroinflammation are trig-
gering neurodegeneration in AD [1]. Various therapeutic
approaches have been developed to prevent generation or
aggregation of Aβ in the brain, or to remove insoluble Aβ.
The clinically most advanced approach is Aβ immunother-
apy, with a number of phase 3 trials completed, however,
data to date have showed no or only marginal disease
modification [2, 3]. Similar disappointing results have come
from randomized clinical trials of anti-inflammatory drugs,
despite promising data from epidemiological findings [4].
Negative results of Aβ immunotherapy studies in particular
have led to the concept that Aβ targeting therapeutics may
be most efficacious at the pre-clinical stages of the disease.
This is supported by recent findings from longitudinal stud-
ies indicating that Aβ accumulation may be present decades
before disease manifestation [5]. Together this supports
prevention of Aβ formation as a strategy for investigation.
Generation of Aβ may be blocked by inhibiting BACE-1
(β-site APP Converting Enzyme 1) or γ-secretase [6, 7].
Inhibition of γ-secretase has faced serious safety issues,
while drug-like BACE inhibitors were not found within the
chemical space of first generation hydroxyethylene and
ethanolamine scaffolds. The discovery of the cyclic amidine
motif represented a major step forward in BACE inhibitor
development (for a recent overview: [8]), as these rigid and
compact structures allowed designing molecules with im-
proved targeting of BACE-1 in the brain. Several clinical
candidates have emerged from this second wave of BACE-1
inhibitors, and have been investigated in preclinical toxico-
logical studies and in early clinical trials. Compounds MK-
8931, AZ-3293, E-2609, and JNJ-54861911 moved into AD
trials, but their characteristics remain largely unpublished.
Another set of compounds failed to reach long term
clinical trials mainly due to safety issues, including
cardio safety [9], liver marker changes [10], and retinal
toxicity [11, 12]. Incorporating the learnings from
these failures into the design of new BACE-1 inhibi-
tors therefore offers the chance to develop a 3rd gener-
ation of compounds with an improved safety profile,
allowing long term treatment of AD patients.In order to address these problems, our research has
focused on three aspects: (1) an improved metabolism
pattern by introducing a novel scaffold. (2) Excellent brain
penetration, as reduction of the peripheral exposure (the
“body burden”) is expected to improve the overall safety
profile. (3) Very good selectivity over cathepsins D and E.
We discovered a novel structural class of BACE-1 inhibi-
tors, characterized by the amino-1, 4-oxazine core and here
describe compound NB-360 (Fig. 1). Our data on efficacy
in vitro and in vivo, in various preclinical models, as well as
on pharmacokinetics and brain penetration in animal
models show favorable potency and excellent distribution
properties. When investigated in acute and chronic studies
in rodent and non-rodent models, NB-360 substantially
reduced soluble and deposited forms of amyloid-β and
showed reduction of neuroinflammation markers.
Results
NB-360 potency, selectivity, and brain penetration
NB-360 was tested in a series of enzyme inhibition assays
with relevant aspartyl proteases. Potency against the mouse
BACE-1 was equal to the human enzyme (IC50 for both: 5
nM), and equipotent inhibition of BACE-2 was observed
(IC50: 6 nM). NB-360 did not inhibit pepsin or the endoso-
mal/lysosomal cathepsins D and E (IC50 > 250 μM). NB-
360 was a potent inhibitor of Aβ40 release from human
APP-overexpressing CHO cells, with an IC50 of 3 nM in
wtAPP CHO cells and 33 nM in SweAPP CHO cells. The
release of Aβ42 (IC50: 3 nM) and sAPPβ (IC50: 4 nM) in
wild-type APP CHO cells was inhibited with similar po-
tency as the release of Aβ40.
We next investigated the ability of NB-360 to cross the
blood-brain-barrier and reach its target in the brain. In vitro
assays showed moderate to high lipophilicity and high pas-
sive permeation in an artificial membrane model (PAMPA
model, [13]). We used a cellular transport model (MDR1-
MDCK cells) to test for a potential recognition of NB-360
by one of the major efflux transporters in the blood brain
barrier, p-glycoprotein [14]. We found high apical-to-
basolateral permeation; the p-glycoprotein mediated trans-
port in the basolateral-to-apical direction was only slightly
higher. This indicated that p-glycoprotein mediated efflux
was unlikely to play a major role for tissue distribution of
NB-360. Non-specific binding to plasma proteins and brain
homogenate was high (Table 1).
In vivo blood pharmacokinetics and brain penetration
was investigated in the rat. Animals were orally dosed with
30 μmol/kg (13 mg/kg) NB-360, suspended in methylcellu-
lose 0.5 % w/v in water/0.1 % Tween 80 v/v) and killed at 5
time points between 1 and 24 h. Blood and brain were col-
lected and analyzed for NB-360 concentrations. Tmax in
blood was 1 h, and the associated Cmax together with the
AUC-values for total and unbound compound in the blood
and in the brain compartment are shown in Table 2. While
Fig. 1 Structure of LY2811376, RO5508887, and NB-360
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proximately 2-fold higher than in the blood, after correc-
tion for nonspecific binding the unbound concentrations
were very similar. This indicated that the NB-360 pool in
the peripheral and in the central compartment was in
equilibrium, and that efflux at the blood-brain-barrier did
not play a significant role in compound distribution.
NB-360 pharmacokinetics
The pharmacokinetic parameters after intravenous and
oral application of NB-360 were investigated in mice,
rats and beagle dogs and are summarized in Table 3.
Clearance was low in the mouse and higher in the rat.
The clearance from dog blood was very slow and the
volume of distribution was remarkably low, in compari-
son to the other species. Both parameters may be linked
to the very high plasma protein binding in dogs (Table 1).
Oral bioavailability was moderate to high in all species;
these data supported the use of oral dosing in further
pharmacological experiments.
Pharmacokinetics/pharmacodynamics studies of NB-360
in rats
NB-360 was orally dosed to rats at 3, 10, and 30 μmol/
kg, and compound concentrations were measured at dif-
ferent time points over 24 h in blood and in forebrain
(Fig. 2a). NB-360 was rapidly absorbed with a Tmax
around 1 h, and showed a parallel decline in blood and
brain over time. Aβ40 was determined in the brain hom-
ogenate and in CSF (Fig. 2b and 2c), and a dose- and
time-dependent reduction was observed in both tissues.Table 1 Physico-chemical and transport properties of NB-360
Molecular weight 449.5
logP (octanol/water) 3.7
Dissociation constant (pKa) 7.1
Passive membrane permeability (logPe pH 6.8) -3.6 cm s-1
MDR1- MDCK flux apical-basolateral (A-B) 14.1• 10-6 cm s-1
MDR1- MDCK flux basolateral-apical (B-A) 26.3• 10-6 cm s-1
MDR1- MDCK efflux ratio (B-A/A-B) 1.9
Plasma protein binding (rat) 93.8 %
Plasma protein binding (dog) >99 %
Non-specific brain homogenate binding (rat) 97.7 %Maximum activity was between 4 and 8 h, and Aβ40
concentrations returned to baseline after 24 h. Signifi-
cant (>50 %) Aβ40 lowering was observed even at the
lowest dose of 3 μmol/kg, and the effect saturated at
higher doses. At the 30 μmol/kg dose, 90.9 % inhibition
was reached at 4 h, corresponding to 0.06 pmol Aβ40/
mg brain tissues. Although we did not perform a formal
determination of the quantification limit of Aβ40 in rat
brain, previous experience indicated that this was the
practical limit of quantification under our extraction and
analysis conditions. Since NB-360 showed such a pro-
found inhibition even at the 3 μmol/kg p.o. dose, in a
second study we extended the dose range to 0.3 and
1 μmol/kg and calculated an efficacious dose (ED50) of
1.6 ± 0.25 μmol/kg for inhibition of forebrain Aβ40 in
the rat at 4 h (Fig. 2d). Overall, NB-360 was highly po-
tent in the rat, and compound exposure correlated well
to effect.
Effects of NB-360 in dogs
We selected dogs to evaluate the NB-360 pharmacology
in a non-rodent animal model because they are commonly
used for toxicological investigations, and are discussed as
models for human AD [15]. Furthermore dog and human
Aβ show sequence identity. Our pharmacokinetic studies
in dogs (Table 3) showed good oral bioavailability and
much longer half-life, compared to rodents. Based on
pharmacokinetic data, we selected a dose of 0.5 mg/kg
(1.1 μmol/kg) p.o. for a pharmacokinetic/pharmacody-
namic study of NB-360 in young Beagle dogs, carrying an
implanted ventricular port for repeated CSF sampling.
Blood and CSF were sampled before treatment (at -24 and
at -1 h) and at various time points after oral dosing, up to
168 h. The pharmacokinetic profiles of NB-360 in blood
and in CSF were very similar (Fig. 3a). The peak concen-
tration of 0.7 μM was reached in blood quickly after dos-
ing. At the 168 h time point, NB-360 concentrations wereTable 2 NB-360 concentrations in rat blood and brain, after a
30 μmol/kg oral dose
Blood Brain
Cmax (1 h, μM) 1.62 4.01
AUC 0-24 h (μM•h) 10.2 23.6
unbound AUC 0-24 h (μM•h) 0.63 0.54
Table 3 Pharmacokinetic parameters of NB-360 after oral and
intravenous application in mouse, rat and beagle dog
Parameter Mouse Rat Dog
Dose i.v. (μmol/kg) 2 2 2
Dose p.o. (μmol/kg) 6 6 2
Clearance after i.v. application (ml/min/kg) 16 52 0.4
Terminal half-life after i.v. application (hours) 3.6 2.7 36.2
Vol. of Distribution (l/kg) 4.6 10.2 0.9
Oral Bioavailability (%) 37 92 62
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CSF. The average CSF/blood ratio was 0.023 ± 0.014
(mean ± SD, calculated from n = 20 CSF/blood data pairs).
Without radiolabeled NB-360 being available, we were
unable to accurately determine the plasma protein binding
in dog plasma, Therefore, a precise calculation of the CSF/
free blood ratio could not be done.A
C
Fig. 2 Pharmacokinetics and pharmacodynamics of NB-360 in rats after ora
of vehicle) produced by the doses within each timepoint was tested. a-c: 3
Mean values ± SD are shown, n = 5. a NB-360 exposure in blood and brain. b
kg, # p < 0.01 3 vs 30 μmol/kg c: Aβ40 in CSF, ***p < 0.001 3 vs 10 μmol/kg, $
### p < 0.001 10 vs 30 μmol/kg, d: Dose-response in brain based on 4 h dataThe mean (± SD) level of Aβ40 in the CSF prior to dos-
ing was 5991 ± 1199 pg/ml (2 sampling times -24 h and
-1 h, n = 7), and the predose plasma Aβ40 level was 261 ±
13 pg/ml (mean ± SD, n = 4, -1 h). A single per os adminis-
tration of NB-360 treatment at the dose of 0.5 mg/kg
caused a rapid and long-lasting drop in Aβ concentration
in dog CSF and plasma. All dogs responded strongly to the
treatment, CSF Aβ40 was reduced by approximately 80 %
from 12 to 48 h post dose and slowly returned to baseline
(Fig. 3b). Baseline was reached at about 120 h after the
dose. Vehicle-treated dogs did not show a significant
change of CSF Aβ40 values (Fig. 3c). Plasma Aβ40 levels
responded very quickly (-42 % after 1 h) to NB-360 treat-
ment, the effect reached -70 % after 12 h and very slowly
returned towards baseline, which was not fully reached
even 168 h after the dose (Fig. 3d). Using PK/PD modelling,
we calculated an in vivo IC50 of 59 ± 13 nM of NB-360 in
blood for the reduction of Aβ40 in CSF. Furthermore, theB
D
l dosing. The significance of differences in effect sizes (analyzed as %
μmol/kg (squares), 10 μmol/kg (circles), and 30 μmol/kg (triangles).
Aβ40 in forebrain, *p < 0.05 3 vs 10 μmol/kg, $ p < 0.05 3 vs 30 μmol/
p < 0.05, $$ p < 0.01, $$$ p < 0.001 3 vs 30 μmol/kg, # p < 0.05 and
Fig. 3 Pharmacokinetics and pharmacodynamics of NB-360 in Beagle dogs. a Exposure of NB-360 in blood and CSF of cannulated dogs (mean ±
SD, n = 4) after 0.5 mg/kg p.o. dosing, b concentrations of CSF Aβ40 for the individual dogs, late CSF samples were missing for dogs 1 and 2, c
CSF Aβ40 in vehicle and treatment group, expressed as percent of the mean of the -24 h and the -1 h predose values (mean ± SD), d plasma
Aβ40 in vehicle and treatment groups
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ance rate from dog CSF. We obtained a clearance rate con-
stant k = 0.26 ± 0.07 h-1, corresponding to a half-life of
3.7 h.
Chronic NB-360 treatment in APP51/16 transgenic mice
To find a dosing regimen for chronic treatment, NB-360
was first orally dosed to young (3-5 months) pre-plaque
APP51/16 mice which harbor the human APP751 gene
under the control of the murine Thy1 promotor. This
strain of transgenic mice was selected since it resem-
bles the situation in sporadic human AD, where no
APP mutation is present. Four hours after a 30 μmol/
kg single dose, we observed 79.6 % (n = 5, p = 0.0006)
lowering of TX-100 soluble brain Aβ40, in good agree-
ment with the results obtained in rats. Next, we dosed
the compound p.o. once daily for 4 days at 2 doses to
pre-plaque APP51/16 mice (age: 8 months) in order to
achieve steady state exposure, and measured the Aβ40reduction 24 h after the last dose. When dosing
30 μmol/kg/d, we observed 15.1 % (n = 5, p = 0.02 vs
vehicle) reduction of forebrain Aβ. At the 100 μmol/
kg/d dose, Aβ40 reduction after 24 h was 52.1 % (p =
0.004). In order to achieve a >50 % reduction of brain
Aβ over a 24 h period in mice we selected this dose
for a chronic study.
Female APP51/16 mice at 14.5 month of age (within
the exponential phase of plaque growth) were treated
once daily with 100 μmol/kg p.o. of NB-360 for 6 weeks.
Animals in the baseline group were killed at the age of
14.5 months, before start of dosing. Two out of 17 mice
in the treatment group died during treatment. This level
of loss is within normal ranges for this strain and age of
mice. Mice of the vehicle and treatment groups were
killed at 16 months of age, 4 and 24 h after the last dose
and blood, CSF, and brain were collected. During the
study, we noted the occurrence of patches of grey hair in
the mice of the treatment group. They first appeared
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the treatment group but to a variable degree.
NB-360 exposure and effect on APP metabolites in CSF
and plasma
NB-360 exposure in APP51/16 mouse blood was 3.2 μM
at 4 h after the last dose, and declined to 0.13 μM over the
next 20 h. Concentrations of soluble APP metabolites in
the CSF were determined at 4 and 24 h. The effect on the
BACE-1 dependent APP metabolites correlated with
exposure, with Aβ40 and Aβ42 showing > 90 % reduction
4 h after the dose, and about 60 % at 24 h. Soluble APPβ
(sAPPβ) had a slightly different profile, with less pro-
nounced reduction at 4 h, but stronger effect towards 24 h
(Fig. 4a). As an overall measure of daily efficacy within a
repeated dosing study, we calculated an approximate area
under the effect curve for the 24 h period after the last
dose (AUEC24h from 0, 4, 24 h time points). CSF Aβ40,
Aβ42, and sAPPβ showed almost identical efficacy of
approximately 75 % reduction. Plasma Aβ40 showed a
lower efficacy at the 4 h time point, with an overall
AUEC24h of 70 % reduction (Fig. 4b).
Effect of chronic NB-360 treatment on APP metabolites in
Triton TX-100 extracted forebrain
The effects of NB-360 on the C-and N-terminal APP frag-
ments were quantified in Triton TX-100 forebrain extracts.
C99 and sAPPβ are the membrane-bound and soluble
metabolites, respectively, originating from BACE-1 cleavage
before amino acid 1 of the Aβ sequence. Both showed
about 80 % reduction, 4 h after the last dose, and the effect
returned to 70 % (sAPPβ) and 57 % (C99) reduction at 24 h
(Fig. 4c). Unprocessed, full-length APP as well as the α-
secretase pathway products C83 and sAPPα moderately
increased as a consequence of NB-360 treatment. Their
concentrations did not change considerably between 4 and
24 h, and an average increase of 30 % (full-length APP),
and 50 % (sAPPα and C83) above vehicle control was ob-
served (Fig. 4d).
Effect of chronic NB-360 treatment on Aβ peptides in
formic acid extracted forebrain and amyloid plaques in
cerebral cortex
At treatment start, the baseline group of APP51/16 mice
showed moderate amounts of formic acid (FA)-soluble
Aβ38, 40 and 42. Mice dosed with vehicle had more than
double the amount of FA-soluble Aβ within the 6 weeks
period. Mice treated with NB-360 for 6 weeks had signifi-
cantly lower concentrations for Aβ38, 40 and 42 than the
vehicle group, and were statistically indistinguishable from
baseline (Table 4).
For histological analysis, brain cortical slices were stained
with our in house Aβ antiserum NT12. The total area of
the cortical region of interest that stained positively forNT12 was significantly higher in the vehicle group (0.754 ±
0.074 %, mean ± SEM), compared to the baseline (0.323 ±
0.031 %, p = 0.0012). There was no statistical difference be-
tween the baseline and NB-360 treatment group (0.209 ±
0.054 %, p = 0.093 vs baseline, p <0.0001 vs vehicle). For a
more detailed analysis, Aβ deposits were categorized into
large plaques, small plaques and small, mainly intracellular
granules, and each size group was analyzed separately and
expressed as the number of structures per 3 para-sagittal
cortical sections. Irrespective of the deposit size, the
vehicle-treated animals showed a substantial increase, com-
pared to baseline, and again the NB-360 treated animals
were indistinguishable from baseline (Fig. 5).
Effect of chronic NB-360 treatment on number of activated
microglia and astrocytes
We investigated activated microglia cells (stained with anti-
Iba1) and astrocytes (stained with anti-GFAP) in APP51/16
cerebral cortex. Triple staining for Aβ deposits and
activated astrocytes/microglia cells showed activated cells
were present in the vicinity of large, but also small Aβ
deposits in the cortex (Fig. 6a). During the 6 weeks treat-
ment period, clusters of neuroinflammation increased
substantially in the vehicle compared to the baseline group
(Fig. 6b). The number of GFAP positive and Iba-1 posi-
tive cell clusters in the cortex was substantially lower
in NB-360 treated APP51/16 mice relative to vehicle-
treated mice, reaching values comparable to the base-
line group. We also investigated a possible correlation
between total plaque load, and the Iba1+ and GFAP+
cell clusters and determined a significant correlation
(r2 = 0.77 and 0.70 respectively, p < 0.0001). As shown
in Fig. 6c and 6d, the number of activated innate
immune cells in the brain correlated with the extent
of amyloid deposition.
Discussion
Our optimization of BACE-1 inhibitors in the novel 1,4
-oxazine series resulted in compound NB-360, which
combines low nanomolar potency on the target with
excellent selectivity over the related aspartyl proteases
pepsin, cathepsin D and cathepsin E. This combination is
an important feature, since treatment of rats with high
doses of AMG-8718 caused in retinal toxicity, ascribed to
an impairment of the phagolysosomal pathway in the
retinal pigmented epithelium by off target inhibition of
cathepsin D [12]. Moreover, neuronal lipofuscinosis and
degeneration were reported in rats after treatment with
LY2811376 [11]. Both compounds inhibit cathepsin D in
the low micromolar range (IC50: 3.2 and 15.7 μM,
respectively). In contrast, the IC50 of NB-360 for ca-
thepsin D is >250 μM and no retina toxicity were ob-
served in the eyes of mice after 8 weeks treatment (data




Fig. 4 Effect of NB-360 on APP metabolites in APP51/16 mice, measured in Triton X100 extract 4 and 24 h after the last dose of a 6 week
study (100 μmol/kg/d p.o.). a Aβ40, Aβ42, and sAPPβ in CSF, b Aβ40 in plasma, c Example of forebrain samples on Western blot stained
with C-terminal APP antibody (green) and N-terminal Aβ antibody (red). B: baseline, 14.5 mo, V: vehicle 16 mo, T: treatment with NB-360, d
quantification of Western blot data for C83 and C99. e MSD-immunoassay results for full-length APP, sAPPα, and sAPPβ in TX-100 forebrain
extract. Data are means ± SEM, n = 8-17, all comparisons done against vehicle group
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Table 4 Formic-acid extracted Aβ peptides in forebrain homogenates (pmol/g forebrain)
Aβ species Mean ± SEM NB-360 group,
change vs baseline
NB-360 group,
change vs vehicleBaseline Vehicle NB-360
N 13 17 14
1-38 115.9 ± 38.0 240.3 ± 53.1 77.0 ± 24.9 -33.5 % p = 0.39 -68.0 % p = 0.015
1-40 235.1 ± 37.4 556.1 ± 92.0 197.3 ± 43.4 -16.1 % p = 0.52 -64.5 % p = 0.003
1-42 139.8 ± 25.1 347.6 ± 53.6 106.6 ± 20.9 - 23.7 % p = 0.41 -69.3 % p = 0.0006
Neumann et al. Molecular Neurodegeneration  (2015) 10:44 Page 8 of 15selectivity ratio (IC50 CatD/IC50 BACE-1), but also the
absolute IC50 for cathepsin D are important determin-
ant for such off-target effects.
The physicochemical properties of NB-360 (molecular
weight, lipophilicity, and basicity) are in the known range
for brain-penetrating compounds. Consistent with its phys-
icochemical and membrane transport properties NB-360
showed a moderate to high oral bioavailability and an excel-
lent blood-brain barrier penetration as indicated by similar
free compound concentrations in brain and in blood. Fur-
thermore, NB-360 has favorable pharmacokinetic proper-
ties, such as good oral bioavailability and low clearance in
rodents and in dogs.
The Aβ lowering in brain and CSF of rats was dose- and
time-dependent, with the strongest effect at 4 h, while the
NB-360 brain concentration was highest at ≤ 1 h after
dose. This is in agreement with the proposed mechanism
of action: Inhibition of BACE-1 by NB-360 reduces gener-
ation of new Aβ peptides, but the decline of tissue Aβ
depends on its intrinsic clearance, and is independent of
NB-360. As discussed previously [16], the turnover of
Aβ40 in CSF is relatively fast in rodents, compared to
higher species. The reported clearance rate of 0.48 h-1 for
Aβ40 in rat CSF predicts an 85 % reduction after 4 h of
complete blockade of the BACE-1 enzyme, in reasonable
agreement of the ~90 % reduction observed at the
30 μmol/kg dose. From the dose-dependency a half-
maximal efficacious dose (ED50) of 1.6 ± 0.25 μmol/kg
(0.7 mg/kg) was calculated for NB-360 showing its high
potency in vivo. Our design strategy, with emphasis on
brain penetration, has led to a compound with the desired
level of in vivo potency at low peripheral exposure.
A single dose study of NB-360 at 1.1 μmol/kg (0.5 mg/
kg) in dogs confirmed and extended the findings in rats.
We observed a good PK/PD correlation, with measurable
exposure in blood for 7 days, and the corresponding long-
lasting pharmacodynamic effect on CSF Aβ. In agreement
with the slower intrinsic Aβ clearance in dog CSF (we
found t½ = 3.7 h), it took around 12 h to reach the max-
imum effect. Based on modeling we could calculate an
in vivo IC50 of NB-360 in blood (59 nM) for the reduction
of Aβ40 in CSF. Overall the dramatically lower compound
clearance in dogs versus rats resulted in a considerable
prolongation of the pharmacodynamic effect with almostmaximal Aβ inhibition still after 48 h as compared to 8 h in
the rodents.
Until very recently, LY2811376 and LY2886721 were the
only BACE inhibitors with published structure and efficacy
data in animals and humans. In PDAPP mice, LY2811376
achieved > 60 % reduction of brain Aβ at doses ≥ 30 mg/kg
p.o. At an oral dose of 5 mg/kg in dogs, approximately
70 % reduction of CSF Aβ was achieved. In agreement with
these preclinical data, substantial reduction of CSF Aβ in
healthy volunteers was seen at oral doses of 30 mg (-20 %)
and 90 mg (-54 %) [11]. These results are encouraging, and
suggest that efficacy studies with a BACE-1 inhibitor in
transgenic mice and dogs have predictive value for the
human situation. When compared with LY2811376, NB-
360 scores favorably in terms of dose-related efficacy in
preclinical models. Both in transgenic mice and in dogs, a
comparable treatment response was achieved with NB-360
at approximately 10-fold lower oral doses. Since the brain
penetration of LY2811376 is comparable to NB-360, the
better in vitro potency of NB-360 is most likely the reason
for the higher efficacy. Very recently, data on the more
selective compound LY2886721 were published [10]. The
compound dose-dependently inhibited Aβ in preclinical
models with similar efficacy as LY2811376 and in human
CSF after single and multiple dosing. However, LY2886721
showed an elevation of liver enzymes in a number of AD
patients. Liver toxicity is often related to structural features
of the parent compound or its metabolites, and may not be
a general feature of BACE inhibitors. The structurally dif-
ferent NB-360 and other new compounds will help to bet-
ter understand and to resolve this issue.
Previous studies of BACE-1 deletions (BACE-/+ and
BACE-/-) in the APP51/16 model have shown a non-
linear relationship between BACE-1 enzyme activity
and Aβ generation [17]. While heterozygous BACE
knock out mice had an about 50 % reduced BACE
activity only a moderate (10-30 %) decrease was found
for key APP metabolites of the β-site pathway (sAPPβ,
C99, and Aβ40). A complete reduction was observed
only in the homozygous knock out animals. A study in
BACE -/+ PDAPP mice has shown a similar moderate
effect of reduced BACE1 activity on neocortical Aβ in
young mice (-12 %, [18]). However, at 18 months, total





Fig. 5 Immunohistochemistry for deposited Aβ of APP51/16 mice; a-c examples of mouse cerebral cortex. a Baseline, b vehicle, c: NB-360-
treated mice. d Illustration of the separation of large plaques, small plaques and intracellular granules; continuous arrow > large plaque;
dashed arrow > small plaque; dotted arrow > granules. Size bar = 200 μm. e-g Quantification of cortex area stained positively with NT12
numbers are the sum of deposits in three adjacent sagittal sections, e large plaques, f small plaques, g small deposits
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treatment with NB-360 resulted in 70-75 % reduction in
dogs, calculated as an approximate area under the effect
curve over a 24 h period from the values at 12 and 36 h. In
the dog study BACE-1 inhibition thus must have been farbeyond the 50 % of a homozygous knock out for more than
24 h.
Having demonstrated that NB-360 was a potent inhibitor
of Aβ generation in 2 acute animal models of amyloidogen-
esis, we investigated the effect on Aβ deposition using an
Fig. 6 Effect of NB-360 treatment on the number of GFAP-positive astrocytes and Iba-1 positive microglia cell clusters illustrating accumulation of
astrocytes and microglia in the vicinity of amyloid plaques. a Triple staining of cerebral cortex for aggregated Aβ (blue), GFAP (red) and Iba-1
(green). b Quantitative analysis of GFAP+ and Iba-1+ clusters in cortex. Shown are mean ± SEM, **p < 0.01 (Dunnett’s multiple comparisons test)
c: correlation of total Aβ stained area in cortex with GFAP+ clusters. d Correlation of total stained Aβ area in cortex with Iba-1+ clusters. Solid line
represents the linear fit, and dashed lines the 95 % confidence interval
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data [19] suggest that mice overexpressing the “Swedish”
mutation at the BACE cleavage site are less sensitive to
BACE inhibitors than models with human wild-type APP,
although we achieved substantial Aβ reduction in mice with
the “Swedish” mutation (APP23) as well (unpublished data).
A recent study with centrally delivered BACE inhibitors in
Tg2576 showed significant efficacy in a “Swedish” mouse
model [20]. However, as wild-type APP better represents
the situation in the majority of AD patients, we chose our
wild type APP mouse line, APP51/16, for use in a chronic
study. APP51/16 does not carry additional mutation accel-
erating Aβ deposition, and plaque load is moderate unless
the mice are very old. At the age of study commencement
(14.5 months) the total amount of forebrain Aβ40 (~230
pmol/g after formic acid extraction) was about 30-fold
higher, compared to 4 month old pre-plaque APP51/16
mice (~7 pmol/g, [21]). During the treatment period, totalbrain Aβ and amyloid plaques increased more than 2-fold
in the vehicle group, compared to baseline. However, the
group treated with NB-360 showed no increase of Aβ
versus baseline, and neither large nor small plaques
were increased. In this regard, no reductions in Aβ or
Aβ deposition were found relative to baseline either, it
remains an open question as to whether longer treat-
ment may have the potential to remove existing amyl-
oid deposits in this animal model. In addition to the
extracellular amyloid deposits, the treatment also
reduced the intracellular Aβ staining, which presented
as small granules. Although our treatment period was
shorter, our data can be compared with the data on
RO5508887 [22]. These authors studied the BACE
inhibitor in APP transgenic mice carrying the London
mutation for 4 months of dosing, and observed a
reduction of total deposited Aβ40 by 28 % and of
Aβ42 by 45 %, at a dose of 30 mg/kg. Reduction to
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90 mg/kg, which may be in part a consequence of the
high Aβ42/Aβ40 ratio (~10) which is characteristic for
these mice. There is currently no consensus whether
or not one should aim for a stabilization of plaque
load, or alternatively, for a reduction of the amount of
deposited amyloid-β. Furthermore, it is currently un-
known to what extent findings in transgenic mice will
translate into the human situation. The composition
of plaques in human brain may be different from those
in APP transgenic mice, and in this respect, mouse
data may be of limited value to predict the extent of
the treatment response in humans.
To assess the acute effect of NB-360 we analyzed the
secreted metabolites of the β-site pathway sAPPβ and
Aβ in CSF from the last dose of NB-360 in the chronic
APP51/16 study. We found a strong reduction in all β-site
metabolites at 4 h, which declined by 24 h as observed in
pre-plaque mice after a single dose. This indicated that the
effect of the inhibitor on Aβ generation remained un-
changed over the treatment period of six weeks. In brain a
similar kinetic was also observed for sAPPβ and C99.
Moreover, a shift of APP processing from the β-site cleav-
age to cleavage by α-secretase as a consequence of BACE-1
inhibition was demonstrated by the increase in sAPPα and
C83. In addition, we found full-length APP was increased
by approximately 30 %, suggesting that the competing
α-secretase pathway can only partially compensate for
this level of BACE-1 inhibition in the APP51/16 mouse
model. This pattern of changes in APP metabolites dem-
onstrates that NB-360 acted as a genuine BACE-1 inhibi-
tor during chronic treatment in vivo and confirms the
mechanism of action for the Aβ reduction.
Neuroinflammation is another important component
of AD pathology, which is postulated to be a response
of the brain to amyloid-β deposition [23]. Microgliosis
in particular has been described in very early publica-
tions as a prominent feature in the AD brain, and
there is substantial data supporting the concept that
amyloid-induced pro-inflammatory cytokines, reactive
oxygen species and other inflammatory mediators play
a key role in neurodegeneration, synaptic, and tau
pathology in Alzheimer’s disease [24, 25]. We therefore
determined the numbers of activated microglia and astro-
cyte cell clusters in the cerebral cortex of APP51/16 mice
as an indicator of brain inflammation. Triple staining of
cortical slices showed clusters of both activated microglia
cells as well as astrocytes in the vicinity of amyloid plaques
already at baseline, the number of which increased in the
vehicle group. Treatment with NB-360 significantly re-
duced the number of IBA1 positive, activated microglia
cells and GFAP positive astrocyte clusters, compared to the
vehicle control group, reaching the value of the baseline
group. Activated microglial and astrocyte cell clustersshowed a clear correlation with amyloid plaques as
well as among each other. CD68 staining, specific for
phagocytic microglia cells was used in the study of Thakker
[21]. The authors found a higher number of CD68 positive
cells surrounding the plaques in the treatment group, com-
pared to vehicle. This and our finding regarding microglia
are not mutually exclusive and may be related to different
treatment times and stages of amyloid formation in both
studies. They illustrate our limited understanding of the
role and activation status of microglia and/or infiltrating
myeloid cells in AD models and in the context of BACE in-
hibitor treatment. However, both datasets demonstrate that
BACE inhibitor treatment also reduces the inflammation
present in amyloid plaque bearing brain, and support the
notion that neuroinflammation in AD is a response to
amyloid-β deposition.
Patches of grey hair appeared on the mice during chronic
treatment with NB-360. Studies with BACE (-1 and/or -2)
knock out mice has implicated both genes in hair pigmen-
tation [26]. Since NB-360 shows low nanomolar inhibition
of BACE-1 and -2, the appearance of grey hairs may be
related to the selectivity profile of the compound. The
mechanism of this hair discoloration has been investigated
further and will be reported in due course. The human rele-
vance of this finding is currently not understood and re-
quires further investigation.
Conclusion
The data demonstrate that NB-360 is highly potent in vitro
and has an attractive combination of drug-like properties,
leading to strong direct effects on amyloid pathology
in vivo. Furthermore, using NB-360 as an example, we
show that, at least in an APP-transgenic mouse model,
amyloid-β deposition and neuroinflammation are corre-
lated, and that a BACE-1 inhibitor, which effectively stops
further amyloid-β deposition, can also have marked effects
on the downstream neuroinflammation. There is a substan-
tial body of literature showing that Aβ plaques are associ-
ated with micro-and astrogliosis (reviewed in [27]) and the
concept that reducing Aβ may prevent downstream path-
ology forms the basis of the amyloid hypothesis [28]. Our
findings indicate that reduction in amyloid-β via inhibition
of BACE-1 may have the desired beneficial downstream
effects on Alzheimer’s disease pathology.
Methods
In vitro protease and Aβ-release assays
Human and mouse BACE-1 as well as human BACE-2 was
expressed as recombinant catalytic domain. NB-360 was
diluted to final concentrations from 1 nM to 10 μM, incu-
bated with enzyme, and residual activity measured using a
FRET substrate with a BACE-cleavable sequence. Cathepsin
D and cathepsin E was activated from the corresponding
pro-enzymes. Porcine pepsin was the native full-length
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concentrations from 1 μM to 250 μM, and residual activity
was measured using Mca-GKPILFFRLK(DNP)D-R-NH2.
Percent inhibition was plotted vs inhibitor concentration,
and the IC50 values were calculated using a 4-parameter
logistic model. IC50 values represent the average of 8 com-
pound batches. Chinese Hamster ovary cells stably trans-
fected with human APP751 (both wild-type and “Swedish”
sequence) were used to measure NB-360 effect on APP
metabolism. Cells were incubated with NB-360 (3 nM-
10 μM) for 24 h, and supernatant was analyzed for
Aβ40, Aβ42 and sAPPβ using in house or commercial
immunoassays.
Profiling assays
The octanol/water distribution coefficient was derived
from the apparent permeability across an artificial liquid
membrane [29]. The PAMPA assay was done as de-
scribed [15]. MDCK cells overexpressing human p-
glycoprotein (MDR1-MDCK cells, obtained from Prof.
A. Berns, Netherlands Cancer Institute) were grown on
HTS Multiwell plates, 1 μm pore size (Becton Dickinson).
After formation of a tight monolayer, NB-360 was applied
to either the upper or the lower chamber. After one hour,
liquid was removed from the upper and lower chambers
and analyzed by HPLC-MS. Apical-to-basolateral and
basolateral-to-apical transport rates were calculated. Non-
specific binding of NB-360 to rat and dog plasma and to
rat brain homogenate was determined by rapid equilib-
rium dialysis as described [30].
Animals
All animal experiments were conducted with the
approval of the Cantonal Veterinary Authority of Basel
City, Switzerland. Pharmacokinetic studies used male
Sprague Dawley rats, C57BL6 mice and Beagle dogs,
obtained from Charles River (France, rodents) and
Marshall (Italy, dogs). NB-360 was dosed intraven-
ously as a solution (NMP/PEG200 based mixtures)
whereas for oral dosing, NB-360 was suspended in
methylcellulose 0.5 % (w/v) / 99.5 % water/0.1 % Tween
80 and applied via oral gavage. Blood was collected i.v., by
sublingual bleeding or at sacrifice whereas a serial blood
sampling allowed obtaining individual PK profiles in these
species. Blood samples were taken between 5 min (intra-
venous) and 15 min (oral) up to 24 h (mice), 48 h (rat)
and 408 h (dog). Brain exposures were determined in the
pharmacological studies by collecting the brain after de-
capitation at selected time points after dosing.
Bio analytical methods
Brain samples were homogenized with 2 mM KH2PO4 buf-
fer (approx. 1/2, w/v). A structurally similar internal stand-
ard was added to the blood or brain homogenate samplesand NB-360 was extracted by quenching with a fourfold
volume of acetonitrile and an aliquot of the supernatant
was directly injected into the LC/MS/MS system. NB-360
was separated from endogenous components using a
reverse phase column and a gradient elution with Water/
1% formic acid and acetonitrile/1% formic acid. NB-360
was ionized with positive electrospray mode and quantified
in MRM mode. The LLOQ ranged between 0.4 and 2 ng/
mL in blood and 1.2 ng/g and 6 ng/g in brain.
PK data analysis
The absorption and disposition parameters were esti-
mated by a non-compartmental analysis of the mean
blood concentration (n = 3 mice) or individual concentra-
tion (rats, dogs) versus time profile after oral and intraven-
ous administration.
Pharmacokinetic/pharmacodynamics studies
Rat studies used male Charles River Sprague-Dawley rats of
approx. 300 g body weight. Female transgenic APP51/16
mice (C57BL/6 background strain) were bred in-house.
APP51/16 mice express human wild-type APP751 under
the control of a Thy-1 expression cassette in brain neurons,
and are characterized by mostly cortical, but few vascular
amyloid-β deposits. [21, 31]. Mice were used at the pre-
plaque stage (<10 mo.) and during the exponential phase of
plaque growth (14.5-16 mo.). Dosing was per os in a dose
volume of 10 ml/kg for mice and 5 ml/kg for rats. NB-360
was dosed either as a hydrochloride salt in water and 2 %
cremophore EL (rat dose response and single dose study in
pre-plaque APP51 mice) or in all other studies as a free
base in a fine suspension in water:methylcellulose:Tween80
(0.5:0.1:99.4). Rodents were deeply anesthetized for CSF
sampling from the cisterna magna, accessed through the
exposed atlanto-occipital membrane. CSF was harvested
into protein lo-bind Eppendorf tubes and frozen on dry ice.
Animals were decapitated while anesthetized and blood
and brain samples collected. Brains were briefly rinsed in
PBS, quickly wet-dissected and samples frozen on a metal
plate precooled on dry ice. All samples were stored at -80 °
C until analysis. The dog study was carried out at Charles
River Laboratories, Canada. Male dogs were used with n =
4 per group. A cannula with an access port was implanted
under anesthesia, to allow serial CSF sampling from the
lateral ventricle. Dogs were allowed to recover from the
surgery for 2 weeks before the start of the experiment. NB-
360 was applied at 1.5 mg/kg in methylcellulose:Tween
80:water (0.5:1:98.5).
Brain homogenization and extraction
Frozen rodent forebrains were homogenized in 9 volumes
of ice-cold Tris-buffered saline (pH 7.4) containing
Complete protease inhibitor cocktail (Roche Diagnostics,
Penzberg, Germany) using a Sonifier 450 (Branson) and
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extracted by mixing 50 μl 2 % Triton X-100 with 50 μl
homogenate, incubating for 15 min on ice with vortexing,
followed by ultracentrifugation at 100000xg for 15 min.
The clear supernatant was diluted to a final forebrain dilu-
tion of 1:100 and used for analysis. For the extraction of
insoluble amyloid peptides, 50 μl forebrain homogenate
was mixed with 117 μl of 100 % formic acid and stored on
ice for 15 min with vortexing. Samples were neutralized
with 950 μl 1 M Tris base, containing Complete protease
inhibitor cocktail (Roche, Basle, Switzerland) and stored
overnight at room temperature. The supernatant after
15 min centrifugation at 14000 rpm was used for analysis.
Determination of amyloid-β peptides and APP fragments
Aβ38, 40 and 42 were determined using the electro-
chemiluminescence immuno assay kits from Meso Scale
Discovery (Rockville, MD, USA) in either singlet or triplex
format. Samples and standards were prepared according to
the manufactures protocols. The kit based on the antibody
4G8 was used for rat forebrain and CSF samples, and kits
based on 6E10 were used for dog CSF or plasma and
APP51/16 brain and CSF samples. Soluble APPα and
sAPPβ from APP51/16 mice were determined from the
100000xg supernatant and analyzed with Meso Scale
Discovery commercial kits. C-terminal fragments C83 and
C99 were determined from Western blots. Forebrain
homogenates dephosphorylated with lambda protein phos-
phatase as described [21] and run on a 10 % Tris-bicine gel
with 8 M urea. After transfer to Immobilon P membranes
(Bio-Rad Bedford MA USA), bands were probed with APP
C8 antibody (recognizing the C-terminus of APP) and de-
tected with goat anti-mouse IgG Fab fragment Alexa-
Fluor680 (Invitrogen). The same gel was used to visualize
Aβ1-38, 1-40, and 1-42 using the N-terminal antibody
beta1 and goat anti rabbit IgG IRdye 800CW (Odyssey).
Full-length human APP was detected using an in
house immunoassay based on the MSD ECL system as
described [17].
Immunohistochemistry and image analysis
Antibodies and dilutions used were: NT12 (1:1000,
Novartis internal rabbit polyclonal against Aβ), 4G8
(1:1000, Covance), anti-Iba1 (1:200; polyclonal rabbit
antiserum; WAKO), anti-GFAP (1:5000, rabbit poly-
clonal DAKO and 1:200 goat polyclonal, Abcam), Sec-
ondary detection antibodies: Biotin-labeled goat anti-
mouse (DAKO), biotinylated goat anti-rabbit (DAKO),
Alexa 594-labeled chicken anti-goat IgG (1:500, Invi-
trogen); Alexa 488-labeled labeled goat anti-mouse
IgG (1:500, Invitrogen), Alexa350-labeled goat anti-
rabbit IgG (1:500, Invitrogen).
Automated immunohistochemistry of paraffin sec-
tions was performed on 4 μm para-sagittal paraffinsections mounted on SuperFrost + slides and automat-
ically immunostained using the Discovery XT technol-
ogy (Ventana/Roche Diagnostics). Briefly, sections were
de-paraffinized, rehydrated, subjected to antigen retrieval
by heating with CC1 cell conditioning buffer, incubated
for 60 min at room temperature with primary antibody di-
luted in antibody diluent, incubated with the respective bi-
otinylated secondary antibody diluted in Ventana antibody
dilution, reacted with DABMab kit and counterstained
with blueing reagent (Ventana/Roche Diagnostics).
Manual immunofluorescence staining of paraffin
sections was performed on 4 μm sagittal paraffin sec-
tions. They were de-waxed and subjected to antigen
retrieval by microwaving for 10 min at 98 °C in 0.1 M
citrate buffer pH 6.0 and rinsed in PBS. Sections were
subsequently incubated for 1 h with PBS containing
2 % goat serum, reacted over night at 4 °C with anti-
body diluted in PBS containing 2 % goat serum,
washed 3 times in PBS, incubated for 1 h at room
temperature with the respective fluorescent labeled
secondary antibodies and mounted with Prolong Gold
(Invitrogen).
β-amyloid staining was assessed by digital image ana-
lysis. Digital images of slides were captured with a Mirax
scanner (Zeiss, 20x magnification) equipped with an
Axiocam camera (Zeiss) for fluorescence images, and a
Marlin camera (Vision Technologies) for bright-field im-
ages. Immunostained plaques and deposits (DAB stain-
ing) in 3 para-sagittal mouse brain sections within the
cortex were quantified by digital image analysis: For the
quantitative plaque evaluation, a proprietary image ana-
lysis platform (ASTORIA, Automated Stored Image
Analysis) was developed based on MS Visual Studio
2010 and many functions from Matrox MIL V9 libraries
(Matrox Inc, Quebec, Canada).
For the beta-amyloid plaque analysis, the following se-
quence of steps was performed: 1. Slides were scanned
with Mirax (20x magnification) 2. Manual outlining of
regions of interest defining cortex in brain sections for
Aβ plaque assessment 3. Running the in-house devel-
oped ImageScope (Aperio Inc., USA) plug-in for cre-
ation and export of *.tif image tiles (at 14x mag).
Image batch processing was done as follows: 1.Color
deconvolution 2. Detection of nuclei and exclusion of
their surrounding from valid plaques 3. Adaptive thresh-
olding technique for segmentation of brown objects 4.
Rejection of unspecific granular clusters 5. Feature based
object classification into 3 categories: intracellular Aβ
(25 - 200 pixels or within nuclear vicinity), small plaques
(200 … 1000 pixels and sufficiently detached from nu-
clei), large plaques (>1000 pixels).
Significance of differences in β-amyloid staining be-
tween groups was statistically evaluated by Dunnett’s
multiple comparisons test.
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Animals were pseudo-randomly allocated to treatment
groups such that body weight difference between groups
was minimized. IC50 and EC50 curves were fitted with
four-point variable slope dose-response curves. To analyze
effects of treatments on groups, data were first tested to
determine if they met assumptions for parametric testing
(Kolmogorov-Smirnov test (with Lilliefors’ correction) nor-
mality test and equal variance tests). Data that met assump-
tions for parametric analyses were analyzed using 1-way
ANOVA followed by the Tukey test for post-hoc compari-
sons if significant main effects were determined in the
ANOVA. Data that did not meet assumptions for paramet-
ric analyses (i.e. the time course data in rats) were analyzed
using Kruskal-Wallis One Way Analysis of Variance on
Ranks followed by Tukey test, as stated above. Correlations
were made using Pearson’s correlations. Data were analyzed
using Origin (V8.1, MicroCal) or Sigma Plot Version 12.3,
(Systat Software Inc.). Two CSF samples were excluded
from rat kinetic data analyses because of visible blood
contamination (a pre-defined exclusion criterion). Since
only n = 4 dogs were used in CSF experiments, data are
presented without statistical analysis.
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